Oncolytic peptides are highly effective on remodeling the tumor microenvironment and potentiating the anticancer immunity through multiple mechanisms, particularly by inducing immunogenic cell death. Intriguingly, a recent study demonstrates that LTX-315, one of the most promising and extensively studied oncolytic peptides, inhibits PD-L1 expression via ATP11B, thus enhancing the effectiveness of cancer immunotherapy by targeting the PD-1/PD-L1 axis. Therefore, this commentary discusses the broad effects and perspectives of oncolytic peptides on anticancer immunity, further highlighting the potential issues and directions of oncolytic peptides in cancer immunotherapy.
Keywords: Drug Therapy, Combination; Immunotherapy; Oncolytic Virotherapy; Programmed Cell Death 1 Receptor; Tumor Microenvironment.
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.